We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Vaccine Design and Testing – Products

The Race Isn’t Over Yet - Efficient Discovery, Development and QC of Antibodies content piece image
Product
Advertisement

The Race Isn’t Over Yet - Efficient Discovery, Development and QC of Antibodies

Octet® BLI platforms are helping accelerate research on Coronavirus by providing:

High-throughput kinetic interaction analysis solutions to rapidly select and characterize vaccine and therapeutic candidates

Efficient workflows for vaccine and biotherapeutic development research

Fast and flexible platform 

Versatile solutions in upstream and downstream vaccine development
Latest Tools for COVID-19 Omicron Variant Research content piece image
Product News

Latest Tools for COVID-19 Omicron Variant Research

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529) content piece image
Product News

Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Sino Biological, Inc. has announced that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Charged Aerosol Detectors - Ensure Vaccine Efficacy content piece image
Product
Advertisement

Charged Aerosol Detectors - Ensure Vaccine Efficacy

Charged Aerosol detection (CAD) can be used to complement your HPLC-UV analysis in a situation where excipients in a formula are a mix of UV active and inactive components. Using these tools together gives you a robust and reliable analytical detection method to determine the stability of all vaccine excipients.
BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines content piece image
Product News

BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines

BioNet and BIA Separations, now part of Sartorius, have announced the successful development of an optimized mRNA manufacturing process.
908 Devices To Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows  content piece image
Product News

908 Devices To Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

At the American Society of Mass Spectrometry conference October 31 to November 4 in Philadelphia, 908 Devices Inc. presented several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications.
mRNA Vaccine Approvals for COVID-19 content piece image
Whitepaper

mRNA Vaccine Approvals for COVID-19

In this cell and gene therapy insights expert roundtable, a panel of four experts will answer some central questions surrounding the development of novel biotherapeutics.
CLINAM Releases Computer Modelling Study To Minimise COVID-19 Deaths content piece image
Product News

CLINAM Releases Computer Modelling Study To Minimise COVID-19 Deaths

Personalized vaccine strategies minimize deaths and case numbers in a Coronavirus wave of "Variants of Concern" when vaccine supply is limited, a modelling study from Switzerland predicts
Advancing the Development of Therapeutics Against Infectious Diseases content piece image
Whitepaper

Advancing the Development of Therapeutics Against Infectious Diseases

Novel and emerging infectious diseases can be a serious threat to human health and the global economy, as exhibited by the current SARS-CoV-2 outbreak. To mitigate these threats, it is necessary to initiate comprehensive containment strategies such as
Adjuvants for Immunotherapy and Vaccine Development content piece image
App Note / Case Study

Adjuvants for Immunotherapy and Vaccine Development

Download this flyer to discover various monophosphoryl lipid A (MPLA) adjuvants as well as a trehalose dibehenate and DDA adjuvant system for tuberculosis vaccines.
Advertisement